Joseph Edelman created perceptive Advisors in 1999. He has a personal net worth of $2.9 billion and oversees more than $15 billion in securities. According to Forbes’ list of the wealthiest Americans in 2021, Edelman is ranked 389th. In the field of biotechnology investing, Joseph Edelman is regarded as a “rock star.” His Perceptive Advisors focuses on biotech stocks in the small and mid-cap range. From 1999 to 2003, the hedge fund had positive returns during the first five years.
Insider Monkey highlights the top 10 biotech stocks from the second quarter portfolio of Joseph Edelman’s Perceptive Advisors. The Virginia-based firm Landos Biopharma, Inc. specializes in developing and manufacturing oral medicines for autoimmune illnesses. With 14.87 million shares valued at about $171.7 million, Perceptive Advisors is the largest shareholder in Landos Biopharma, Inc. VBI Vaccines Inc. is a Massachusetts-based startup working on infectious disease and cancer treatments. According to Joseph Edelman’s Perceptive Advisors, the company is placed ninth on the list of the ten finest biotech companies to purchase. Horizon Therapeutics is a biotech business that develops drugs to treat severe inflammatory and autoimmune illnesses. According to Joseph Edelman’s Perceptive Advisors, the company is ranked eighth on the ten finest biotech companies to purchase. Collegium Pharmaceutical, Inc. focuses on the development of chronic pain therapies. On the list of the top ten biotech stocks to buy, the company is ranked seventh. Perceptive Advisors, led by Joseph Edelman, is the largest shareholder, owning 17.5 million shares worth $189.7 million. Amicus Therapeutics, Inc. is a biotech company focused on developing medicinal treatments for rare metabolic illnesses. According to Joseph Edelman’s Perceptive Advisors, the company is ranked sixth on the list of the ten finest biotech companies to buy. For more details, click 10 Best Biotech Stocks To Buy According To Joseph Edelman’s Perceptive Advisors.